Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27752370 | 0.88 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2HTR1AHTR1D | |
| SCHEMBL2946591 | 0.83 | SLC6A4 (0.56) | SLC6A4SLC6A3ABHD6DAGLANR1H2 | |
| SCHEMBL2945622 | 0.80 | HTR6 (0.43) | ABHD6DAGLANR1H2NR1H3GPR119 | |
| SCHEMBL2949575 | 0.76 | ABHD6 (0.44) | ABHD6DAGLANR1H2NR1H3GPR119 | |
| SCHEMBL27773232 | 0.75 | ABHD6 (0.43) | ABHD6DAGLANR1H2NR1H3GPR119 | |
| SCHEMBL18838004 | 0.75 | GPR119 (0.46) | ABHD6DAGLANR1H2NR1H3GPR119 | |
| SCHEMBL2951669 | 0.72 | HTR6 (0.45) | ABHD6DAGLANR1H2NR1H3GPR119 | |
| SCHEMBL2948211 | 0.72 | SLC6A2 (0.42) | SLC6A4SLC6A3ABHD6DAGLANR1H2 | |
| SCHEMBL443134 | 0.71 | SLC6A2 (0.42) | SLC6A4SLC6A3GPR119SLC6A2HTR1A | |
| SCHEMBL19838409 | 0.71 | RET (0.48) | SLC6A4SLC6A3GPR119SLC6A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061774-B1 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2061774-B1 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2061774-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019971-A2 | ARYLPIPERAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045543-A1 | Arylpiperazine derivatives and uses thereof | CYP3A7, CYP3A5, HTR7 | SLC6A4 1438/4885SLC6A3 1264/4885ABHD6 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.